Biohit Launches New Electronic Pipette for Precise Dispensing in Small Volumes
Published: Jun 20, 2011
Biohit will launch the pipette under the commercial name eLINE 0.1 – 5 µl and it will be available globally as of June 27th 2011. The pipette is suitable for handling 0.1 – 5 micro litres of liquid and is targeted especially for molecular biology laboratories. The new pipette complements Biohit’s range of single channel pipettes.
Biohit has the world’s largest range of single and multichannel pipettes and the company is the market leader in electronic pipettes. Biohit also manufactures pipettes to many leading brand owners as an OEM partner. In 2010, over 90% of Biohit’s net sales of MEUR 40 were generated by pipettes and connected products and services.
Biohit is a globally operating Finnish biotechnology company that was established in 1988. The company’s mission is to improve human health and quality of life. The company follows a goal-directed and long-term innovation and patenting strategy.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. The end users of Biohit’s products are e.g. the pharmaceutical industry, the food industry, research institutes and universities as well as the public and private healthcare sectors.
Biohit has two business segments: Liquid Handling and Diagnostics. Liquid Handling products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services. The Diagnostics business comprises products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases, such as the blood-sample based GastroPanel examination for the diagnosis of stomach illnesses and associated risks, and Acetium capsules, which bind carcinogenic acetaldehyde in the stomach.
In 2010, Biohit’s net sales were MEUR 40 and the company employed approximately 400 people. Biohit is headquartered in Helsinki, Finland, and has production facilities in Helsinki, Kajaani and in Shanghai, China. It has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA. The company also has a representative office in Singapore. Biohit's products are also sold through about 200 distributors in 70 countries.
Biohit's Series B share is quoted on NASDAQ OMX Helsinki in the Small Cap/Healthcare group and is traded under the code BIOBV.
More information: www.biohit.com.
CEO, Biohit Oyj
Tel. +358 9 773 861, mobile +358 400 701180